Is the Indigenous Td Vaccine a Milestone for India's Atmanirbhar Health Sector?
Synopsis
Key Takeaways
New Delhi, Feb 21 (NationPress) Union Health Minister JP Nadda unveiled the indigenously produced Tetanus and Adult Diphtheria (Td) vaccine at the Central Research Institute located in Himachal Pradesh, deeming it a pivotal advancement in enhancing India’s public health framework and realizing self-sufficiency in healthcare.
The vaccine's launch took place at the Central Research Institute in Kasauli, Himachal Pradesh. During his address to scientists, technical experts, and staff, Nadda commended the institute for its achievement in developing the vaccine within India and termed the event as historic.
“This launch signifies a crucial milestone in reinforcing national health security and fortifying the country’s public health infrastructure,” he remarked.
“Led by Prime Minister Narendra Modi, our government has established definitive goals aimed at attaining self-reliance in the health and pharmaceutical sectors,” the minister emphasized.
Nadda asserted that the indigenous Td vaccine is a tangible step towards the vision of Atmanirbhar Bharat in the healthcare arena.
With its official introduction, the Td vaccine will be made available under the Universal Immunization Programme (UIP).
The Central Research Institute is set to provide 5.5 million doses to the program by April 2026.
Production is anticipated to increase in the forthcoming years to bolster the immunization campaign across the nation.
Nadda highlighted India’s international reputation, indicating that the country is recognized as the “pharmacy of the world” and ranks among the top vaccine manufacturers globally.
“India has attained Maturity Level 3 in the World Health Organisation’s global assessment of regulatory frameworks, showcasing the robustness of its vaccine regulatory system,” he noted.
The Minister also reflected on how vaccine development timelines were significantly longer in the past.
He pointed out that the development of the tetanus vaccine took decades globally, tuberculosis treatments took nearly 30 years to evolve, and the Japanese Encephalitis vaccine required extensive scientific endeavors over the years.
“In stark contrast, during the COVID-19 pandemic, India succeeded in developing two indigenous vaccines within a mere nine months and administered over 2.2 billion doses, including booster shots,” Nadda explained.
He further mentioned that vaccination certificates were issued digitally, demonstrating India’s progress in digital healthcare.
Referring to the Vaccine Maitri initiative, Nadda stated that India supplied COVID-19 vaccines to close to 100 countries, of which 48 received them at no cost.
“Public sector entities like CRI have strengthened India’s capability to satisfy both domestic and international demands,” he concluded.